Company: IXHL
Filing Date: 2025-04-07
Form Type: 424B5
Source: 0001213900-25-029414
Chunk: 40

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-07
Form: 424B5
Chunk 40
---
 or Securities Act, and Section 21E of the Exchange Act. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or our future performance, and they are based on our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect,” “possible,” “likely,” “probable,” and similar expressions that convey uncertainty of future events or outcomes identify forward-looking statements. These statements include, among other things, statements regarding:

| ● | our                                                                                         
 ability to implement our product development and business strategies, including our ability 
 to continue to pursue development pathways and regulatory strategies for IHL-42X, PSX-001,  
 and IHL-675A and any of our other drug candidates;                                          |

| ● | estimates                                              
 regarding market size and related future growth rates; |

| ● | our                                                                                       
 research and development activities, including clinical testing and manufacturing and the 
 related costs and timing;                                                                 |

| ● | the                                                                                      
 possibility that we may be required to conduct additional clinical studies or trials for 
 our drug candidates and the consequences resulting from the delay in obtaining necessary 
 regulatory approvals;                                                                    |

| ● | the                                                                                       
 timing, scope or likelihood of regulatory filings and approvals and our ability to obtain 
 and maintain regulatory approvals for our drug candidates for any indication;             |

| ● | the pricing,                                                                       
 coverage and reimbursement of our drug candidates, if approved and commercialized; |

| ● | the                                                                               
 rate and degree of market acceptance and clinical utility of our drug candidates; |

| ● | our                                                                                       
 expectations around feedback from and discussions with regulators, regulatory development 
 paths and with respect to Controlled Substances Act designation;                          |

| ● | our                                                                                           
 ability to maintain effective patent rights and other intellectual property protection for    
 our drug candidates, and to prevent competitors from using technologies we consider important 
 to the successful development and commercialization of our drug candidates;                   |

| ● | our                                                                                               
 estimates regarding expenses, revenues, financial performance and capital requirements, including 
 the length of time our capital resources will sustain our operations;                             |

| ● | our                                                                
 ability to commercialize drug candidates and to generate revenues; |

| ● | our                                                                                       
 financial condition, including our ability to obtain the funding necessary to advance the